Next, it was of interest to examine whether the effects described above were associated with inhibition of EGFR and/or HER-2 activation as a number of studies suggest that aberrant expression of EGFR and HER-2 might be associated with multiple drug resistance in human pancreatic cancer cells (5,6). Here, EGFR is linked to familial pancreatic carcinoma.